Search PubMedSearch

Biomedical subjects

M Bals-Pratsch

Publications and source records attributed to M Bals-Pratsch.

15 recordsLinked to original sources

Cyclic corticosteroid immunosuppression is unsuccessful in the treatment of sperm antibody-related male infertility: a controlled study.

In this double blind cross-over study, 20 infertile men, who had sperm antibodies detected by the mixed antiglobulin reaction (MAR test) in the ejaculate and by the tray agglutination test (TAT) in serum, were treated with 40 mg/day prednisolone or placebo from days 1 to 10 of the partners' menstrual cycle. Patients were randomly allocated to different treatment groups. While group 1 started with placebo followed by verum for three consecutive cycles, group 2 began with verum and continued with placebo. All patients had regular intercourse (n = 19) or intra-cervical insemination at ovulation (n = 1). A post-coital test or a sperm penetration test was performed during verum and placebo regimes. Blood samples were drawn from the male partner at this time to control the efficacy of prednisolone treatment by checking the TAT titre. No pregnancy occurred during prednisolone or placebo treatment. In eight of 12 patients, post-coital testing showed little improvement and antibody titres decreased in seven of 16 patients. Side-effects from medication were reported by eight patients (seven verum and one placebo cycle) and caused treatment to be discontinued in two cases. Five patients' partners conceived at a later stage by intrauterine insemination with spermatozoa prepared by 'swim up' (n = 3) or by in-vitro fertilization (IVF n = 2). Thus high dose corticosteroid therapy was ineffective in achieving pregnancies induced by infertile men positive for antisperm antibodies. Since side-effects of corticosteroids should not be underestimated in otherwise healthy men, other reproductive techniques such as intrauterine insemination or IVF should be offered to such couples.

Adult

[MR findings in patients with idiopathic panhypopituitarism].

High-resolution MR imaging was performed in seven patients with pituitary dwarfism and panhypopituitarism. In five cases MR-findings included absence of the infundibulum and of the normal intrasellar posterior pituitary bright spot, and the presence of a small nodule at the median eminence. The absence of diabetes insipidus in these patients and the signal characteristics of the nodule at the median eminence suggest that the latter may represent a functioning ectopic posterior pituitary lobe. This complex of findings was only observed in patients with complications in the perinatal period (breech delivery) and appears to be the end result of an ischemic or traumatic injury of the infundibular stem. The infundibular defect would explain both the permanent hormone deficiency of the anterior pituitary gland through a disruption of the hypothalamic-hypophyseal portal system and the absence of diabetes insipidus through an ectopic regeneration of the neurohypophysis at the median eminence.

Adolescent

Androgen receptor disorder in three brothers with bifid prepenile scrotum and hypospadias.

Three brothers with congenital transposition of the penis, scrotal hypospadias, bifid scrotum, and bilateral undescended testes are described. Further signs of incomplete virilization, but no gynecomastia were seen. LH and FSH were elevated, whereas testosterone levels were reduced or in the normal range. Serum concentrations of 17-hydroxyprogesterone, dehydroepiandrosterone, androstenedione, 5 alpha-dihydrotestosterone and estradiol measured in two affected brothers were in the normal range. Fibroblasts from scrotal skin biopsies performed in two patients showed normal 5 alpha-reductase activity (419 and 214 pmol.(mg protein)-1.h-1; normal greater than 1), whereas androgen receptors had reduced maximal binding capacity (Bmax 4 and 14 fmol.(mg protein)-1; normal greater than 18) and an increased equilibrium dissociation constant (0.7 and 1.26 nmol/l: normal 0.2 +/- 0.08) indicating a quantitative and qualitative androgen receptor defect. These patients represent a further variant of androgen insensitivity.

17-alpha-Hydroxyprogesterone

Pulsatile GnRH-therapy in oligozoospermic men does not improve seminal parameters despite decreased FSH levels.

In order to evaluate GnRH administration for the treatment of infertile men with elevated serum FSH levels we administered GnRH in pulses via portable electronic infusion pumps initially to seven patients with low sperm counts and high FSH values over 12 weeks and later to nine further patients over 24 weeks who also underwent testicular biopsies. Fifty microlitres containing 5 micrograms GnRH were infused subcutaneously for 1 min every 120 min in the short-term study and every 90 min in the long-term study. Although FSH levels could be lowered in both groups of patients, none showed any improvement in sperm count or other seminal parameters. Therefore, pulsatile GnRH treatment cannot be recommended for therapy of severe oligozoospermia with elevated FSH levels.

Adult

Human and bovine cervical mucus penetration as a test of sperm function for in-vitro fertilization.

Human and bovine cervical mucus penetration tests (n = 57) were performed preceding IVF to test their prognostic value as sperm function tests for IVF. This evaluation also included results from conventional semen analysis and from a computerized sperm analysis system. The bovine cervical mucus penetration test was shown to be at least as valuable as the human cervical mucus penetration test in evaluating sperm function. The migration distance of the vanguard sperm (P less than 0.001) and the sperm density at a fixed migration distance in the mucus column (P less than 0.05) correlated most closely with the IVF results. A clear parallelism with the outcome of the 'swim up' technique was also found. Of the sperm parameters examined, only sperm motility in the ejaculate (P less than 0.05) correlated significantly with the results of IVF. It is concluded that the outcome of a bovine cervical mucus penetration test depends on the same sperm functions as required for IVF. Therefore, this test may be of predictive value in an IVF programme.

Animals

Investigation of the cause of low sperm motility in asthenozoospermic patients by multiple quantitative tests.

Multiple tests were done on the ejaculates of 10 asthenozoospermic patients and nine healthy normozoospermic volunteers in an attempt to identify individually the cause of low sperm motility in these patients. Possible defects in the sperm plasma membrane and the motility apparatus of sperm, and in epididymal function affecting the development of motility, were investigated. The presence of seminal sperm antibodies or any motility-inhibiting factors in the seminal plasma that could be removed by washing were also tested. Each test was positive in only one or two patients but axonemal dysfunction was identified in nine patients. Removal of seminal plasma from asthenozoospermic samples did not improve sperm motility to any greater extent than with donor ejaculates, and the motile sperm of these patients exhibited characteristics mostly similar to those of donors under various incubation conditions. Selection procedures are, therefore, required to obtain samples of good quality sperm from such asthenozoospermic ejaculates.

Autoantibodies

Substitution therapy of hypogonadal men with transdermal testosterone over one year.

Current testosterone substitution therapy either by injectable or oral testosterone esters suffers from markedly fluctuating serum testosterone levels often far above or below the physiological range. Recently, a transdermal therapeutic system (TTS) for the delivery of testosterone was developed which, when applied to the scrotum, provides smooth serum testosterone levels. Here we report results from seven hypogonadal men treated with the TTS for 14 months by applying a new patch every day. In all patients serum testosterone and dihydrotestosterone (DHT) determined 3-5 h after applying a new patch increased significantly and remained within the physiological range during the entire treatment period. The DHT/testosterone ratio remained constant. In 4 of these patients and 2 others under TTS treatment serum testosterone and DHT were also determined over a 24-h period at regular intervals. In these patients serum testosterone levels in the physiological range were seen during the entire observation period, whereas an increase in the DHT/testosterone ratio occurred towards the end of the one-day treatment phase. All patients in the 14-month treatment study were clinically well substituted and responded with good compliance. Clinical chemistry showed no abnormalities during treatment. Thus, the TTS appears to be an effective and safe new modality for the treatment of male hypogonadism.

Administration, Cutaneous

[Does sperm penetration in bovine mucus provide additional information to the "classical" spermiogram and motility characteristics?].

In vitro bovine cervical mucus penetration tests (Penetrak) were performed in 30 patients from our fertility clinic and in 33 healthy volunteers with normal semen characteristics. After 90 minutes maximum penetration by sperm (mm) was measured using a capillary filled with bovine midcycle cervical mucus. At the same time classical (sperm motility [%], concentration [mill/ml] and morphology [% oval heads] ) and computerized semen analyses (Cell Soft) were performed (mean velocity [micron/s], lateral head displacement [micron], beat frequency [Hz] and mean linearity). Multiple regression analysis of the depth of sperm penetration in cervical mucus (mm) yielded those semen parameters which allowed correct prediction of the penetration test in 54% of cases. Sperm concentration, morphology, motility and mean velocity alone accounted of 53% of the predictions. In 46% of cases the outcome of the cervical mucus penetration test could not be predicted, regardless of whether classical or computerized semen analysis was performed. This suggests that factors other than those described above must play a role in this aspect of sperm function.

Female

Treatment of severe oligospermia with human chorionic gonadotropin/human menopausal gonadotropin: a placebo-controlled, double blind trial.

In an effort to evaluate the effect of hCG/human menopausal gonadotropin (hMG) treatment on semen parameters in normogonadotropic men suffering from oligospermia, a double blind, placebo-controlled study was conducted. After 2 basal examinations of seminal parameters and reproductive hormones, 39 men were recruited for the trial. Nineteen men, allocated randomly to the active drug group, received im injections of 2500 IU hCG twice a week in combination with 150 IU hMG three times a week for 13 weeks, while 20 men were treated, following the same injection schedule, with NaCl only. After the 13-week treatment period, follow-up examination was performed, followed by 3 additional examinations at 4-week intervals. Of those men receiving hCG-hMG, 2 induced pregnancies in their wives, while no pregnancies were reported in the placebo group. Sperm concentrations, the percentages of motile sperm, and the proportions of normally formed spermatozoa, however, were similar in the 2 groups at all times. It was not possible to predict the outcome of treatment based on results of GnRH and hCG tests performed before the treatment phase.

Adult

Transdermal testosterone substitution therapy for male hypogonadism.

A transdermal therapeutic system (TTS) for administration of testosterone was tested in healthy and hypogonadal men. To ensure adequate absorption, a testosterone-loaded film was applied to the scrotal skin. The TTS was designed to last for 22 h; over this time serum testosterone levels in normal men were moderately increased, with concentration curves almost parallel to basal levels. Seven hypogonadal patients also responded to TTS testosterone; serum testosterone levels were in the normal range during a 12-week treatment period. There were no side-effects. TTS testosterone offers a new approach to androgen substitution therapy.

Administration, Cutaneous

Indomethacin and oxaprozin lower seminal prostaglandin levels but do not influence sperm motion characteristics and serum hormones of young healthy men in a placebo-controlled double-blind trial.

To evaluate the influence of indomethacin and oxaprozin on reproductive function in healthy young men, 34 volunteers with normal semen parameters were recruited. In a randomized double-blind design, 12 men were treated with placebo, 12 received 600 mg/day of oxaprozin and 10 took indomethacin 25 mg t.i.d. This treatment phase lasted for 14 days after which a follow-up period extended for another 10 weeks. Sperm counts, percentage of motile and normally formed sperm cells, sperm velocity, linearity, lateral head displacement and beat frequency were evaluated by computerized image analysis once before treatment and at weekly intervals during the rest of the study. Prostaglandin levels in seminal plasma were significantly reduced after 2 weeks of treatment and remained suppressed for at least 2 additional weeks. In spite of this long lasting impairment of physiologic prostaglandin concentrations, no changes in any of the measured parameters were detectable when compared with the placebo group. Basal levels of testosterone, estradiol, LH, FSH, TSH and prolactin were unchanged. The response of hypophyseal hormones to a combined GnRH/TRH test before, during and after the treatment also was not affected. Overall, no negative influence of indomethacin or oxaprozin treatment on male reproductive function could be found in healthy volunteers. Since the active treatment phase was only 14 days, one can only speculate about long term effects of the tested drugs on reproductive parameters in men.

Adult

Transcranial magnetic stimulation: influence on plasma levels of hormones of the anterior pituitary gland and of cortisol?

To assess possible side effects of transcranial magnetic stimulation on the release of anterior pituitary gland hormones three different examinations on 10 males were performed following a standardized protocol. Plasma levels of prolactin, FSH, LH, hGH and cortisol were determined before and after stimulation. Cortical stimulation had no specific influence on the plasma levels of the hormones examined.

Adult

Seminal lead and copper in fertile and infertile men.

Lead and copper concentrations were determined by atomic absorption spectroscopy in semen from 18 fertile and 172 infertile men. Significant correlations between copper concentrations in semen and sperm concentration (r = 0.32, P less than 0.001), percentage progressive motility (r = 0.23, P less than 0.005) and normal morphology (r = 0.22, P less than 0.005) were observed, while no such correlation existed for lead. However, semen copper concentrations of infertile men (194.99 +/- 5.70 micrograms l-1) and fertile men (183.39 +/- 14.37 micrograms l-1) did not differ significantly. Mean lead concentration in semen of fertile men was 11.18 +/- 0.62 micrograms l-1 and significantly higher than lead concentration in semen of fertile men (5.61 +/- 0.53 micrograms l-1, P less than 0.006). Reinvestigation of 18 infertile men after 2 years showed a significant drop of lead concentrations in semen from 17.31 +/- 1.41 to 6.94 +/- 1.32 micrograms l-1 (P less than 0.0002), which might be related to the decreasing use of leaded petrol in the Federal Republic of Germany.

Copper

Intra-individual variation of sperm velocity, linearity, lateral head displacement and beat frequency in healthy volunteers.

In an effort to evaluate the intra-individual fluctuations of sperm motion parameters 12 healthy young men with normal semen parameters were recruited. Weekly semen analysis was performed for 13 weeks. Conventional semen parameters such as sperm concentration, percentage of motile and normally formed sperm were determined according to WHO guidelines, while sperm velocity, linearity, lateral head displacement and beat frequency were evaluated by computerized image analysis. Mean and standard deviations (SD) of all parameters were computed for each individual. Coefficients of variation were expressed as the ratio of SD/mean. On average the following coefficients of variation were found: total number of sperm 58 (+/- 5%); concentration of sperm 47 (+/- 4%); lateral head displacement 27 (+/- 4%); volume 24 (+/- 3%); velocity 19 (+/- 2%); linearity 17 (+/- 2%); percentage of motile sperm 12 (+/- 2%); beat frequency: 12 (+/- 2%) and percentage of normally formed sperm 9 (+/- 1%). The low variation of sperm motion parameters and the ease of their determination suggests that computerized motion analysis of sperm may be a valuable research tool to detect subtle effects e.g. of drugs and environmental toxins on reproductive functions in men.

Humans